Dermata Therapeutics, Inc.
DRMA
$1.18
-$0.04-3.28%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.32% | -2.12% | 47.72% | 31.90% | 1.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.02% | 66.46% | 40.65% | 29.68% | -25.92% |
| Operating Income | -78.02% | -66.46% | -40.65% | -29.68% | 25.92% |
| Income Before Tax | -84.57% | -66.28% | -39.92% | -27.82% | 29.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.57% | -66.28% | -39.92% | -27.82% | 29.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.57% | -66.28% | -39.92% | -27.82% | 29.09% |
| EBIT | -78.02% | -66.46% | -40.65% | -29.68% | 25.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.77% | 55.68% | 79.29% | 79.44% | 82.94% |
| Normalized Basic EPS | 74.77% | 55.68% | 79.29% | 79.44% | 82.93% |
| EPS Diluted | 74.77% | 55.68% | 79.29% | 79.44% | 82.94% |
| Normalized Diluted EPS | 74.77% | 55.68% | 79.29% | 79.44% | 82.93% |
| Average Basic Shares Outstanding | 631.62% | 275.26% | 575.95% | 521.79% | 315.04% |
| Average Diluted Shares Outstanding | 631.62% | 275.26% | 575.95% | 521.79% | 315.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
